Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using elastic nano-liposomes to deliver palmitoylethanolamide improved its transdermal delivery and enhanced its skincare effects, with minimal cytotoxicity and no allergic reactions observed.

This study found that FOXN1 haploinsufficiency is a significant genetic factor causing T cell lymphopenia at birth, linked to reduced thymic function in both humans and mice.

This review discusses the mechanisms and engineering techniques for enhancing the targeted delivery of extracellular vesicles in therapies but reports no new clinical findings; the authors encourage further exploration to advance clinical applications.

PEVs effectively deliver minoxidil through skin.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This article presents a theory on the causes and development of telogen effluvium and reports no new clinical findings.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study retrospectively analyzed 3028 patients with telogen effluvium, finding that 6.2% had iron deficiency anemia and vitamin D deficiency was common, especially in women who were more often prescribed vitamin D therapy.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This study found that women with Telogen Effluvium in Thi-Qar Province, Iraq, had significantly lower serum Ferritin and Vitamin D3 levels, suggesting these may contribute to the condition's etiology.

The FDA approved a new Pfizer drug for hair loss in teens.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This correspondence outlines a research aim to evaluate the usefulness of laboratory testing for telogen effluvium to assist in forming evidence-based treatment guidelines, though results are not provided in the abstract.

Mouse Scube3 affects teeth, tongue, vibrissae, and eye development, but not facial structure or limb growth.

In this study, researchers reported telocytes in the dermis of silky fowl embryos at different developmental stages, highlighting their immunophenotypes and interactions with other cells.

This study found that oral vitamin D3 therapy significantly improved hair regrowth in women with telogen effluvium in southern Punjab, Pakistan, especially among younger women not using sunscreen but consuming milk or milk protein.

A woman developed a severe skin reaction called toxic epidermal necrolysis after taking the antibiotic cephalexin.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This review discusses ethanol-based transethosome vesicles for drug delivery through the skin, but reports no new clinical results.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.